If you’ve watched your child struggle to maintain focus during homework while effortlessly concentrating for hours on activities they love, you’ve seen firsthand how attention isn’t about willpower—it’s about how the brain processes information. You’re not imagining the inconsistency, and your frustration is completely valid. This is exactly why researchers continue seeking new approaches to support focus development, and a significant development has just emerged that may expand options for families navigating attention challenges.
Pharmaceutical Company Submits New Medication to FDA
Otsuka Pharmaceutical announced on November 24, 2025, that it has filed a New Drug Application with the U.S. Food and Drug Administration for centanafadine, a once-daily extended-release capsule designed to support focus development in children, adolescents, and adults. The medication represents a first-in-class approach, working as a norepinephrine, dopamine, and serotonin reuptake inhibitor—targeting three neurotransmitter systems rather than the typical one or two.
Four pivotal Phase 3 clinical trials support the submission, including studies with children ages 4 to 12, adolescents ages 13 to 17, and adults ages 18 to 55. In these trials, centanafadine demonstrated statistically significant improvements in focus characteristics compared to placebo, as measured by standardized rating scales. The medication also showed a favorable safety profile and notably low potential for abuse and dependence.
New non-stimulant for focus development just moved closer to FDA approval. It targets 3 brain systems instead of 1—and showed significant improvements in attention AND executive functioning.
Why This Matters for Families
According to the Centers for Disease Control and Prevention, approximately 7 million children and 15.5 million adults in the United States experience attention differences that affect their daily functioning. Many families find that current medication options either produce unwanted side effects or don’t provide adequate support. The potential approval of centanafadine would introduce a non-stimulant option with a unique mechanism of action.
What makes this development particularly interesting is how the medication engages the brain’s serotonin system alongside dopamine and norepinephrine. Research from Massachusetts General Hospital suggests this broader approach may benefit executive functioning skills including time management, organization, and the ability to start and complete tasks. Dr. Timothy Wilens, Chief of Child and Adolescent Psychiatry at MGH, noted the medication’s potential to improve planning and transitional thinking.
As an innovator in mental health, we are pleased to take this important step forward in the hope of providing a novel option to individuals developing their focus capabilities. Centanafadine represents a first-in-class mechanism of action among available approaches, and if approved, may expand the range of options available to those managing attention differences. – John Kraus, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Otsuka Pharmaceutical
Laura Lurns · Learning Success expert
One Tool Among Many
While medication developments grab headlines, they represent just one piece of a comprehensive approach to supporting focus development. Neuroscience research continues to demonstrate that attention skills are trainable through various methods, including structured focus exercises, movement integration, environmental modifications, and skill-building programs. The brain’s remarkable plasticity means that focused practice literally changes neural structure, creating stronger attention networks over time.
For families, this emerging medication option underscores an important principle: parents have choices. Whether through targeted skill training, environmental supports, movement-based approaches, medication, or some combination, there are multiple pathways to helping children develop stronger focus capabilities. The key is finding what works for each individual child’s brain and learning profile.
Key takeaways
- First-in-class mechanism targets three neurotransmitter systems: Centanafadine works on norepinephrine, dopamine, and serotonin, offering a non-stimulant approach with low abuse potential for children, teens, and adults.
- Four clinical trials show significant focus improvements: Phase 3 studies across age groups demonstrated meaningful improvements in attention characteristics and executive functioning skills like planning and organization.
- Parents have expanding options for support: Whether through skill training, environmental modifications, movement-based approaches, or medication, families now have more pathways than ever to help children develop focus capabilities.
What Happens Next
The FDA will now review the application, a process that typically takes 10 to 12 months. If approved, centanafadine would become available for children as young as four years old through adults age 55 and beyond. The medication’s status as a non-stimulant with low abuse potential may make it particularly appealing for families who have concerns about traditional options.
Regardless of how any single medication performs, the broader picture offers genuine hope. Research consistently shows that focus is not a fixed trait but a developable skill. Brains change—rapidly and dramatically—when given the right input. Whether that input comes through medication, targeted training, movement, or environmental changes, children developing their attention capabilities have more options and more reasons for optimism than ever before.
Centanafadine had a significant impact on attention characteristics. It also improves executive functioning—time management, hierarchical thinking, organization, start-stop-shift transitions. – Tim Wilens, M.D., Chief of Child and Adolescent Psychiatry, Massachusetts General Hospital
Laura Lurns · Learning Success expert
Every child developing focus skills deserves access to the full range of approaches that might help their brain work at its best. This potential new option is encouraging not because medication is always the answer, but because it represents expanding choices for families who have been told there’s only one path forward. The system that labels children rather than develops their capabilities continues to fail too many families—but parents equipped with knowledge about brain changeability and multiple intervention approaches hold tremendous power to chart their own course. If you’re ready to discover what specific support would benefit your child most, the Learning Success All Access Program offers a free trial that includes a personalized Action Plan built around your child’s unique learning profile—and you keep that plan even if you decide it’s not the right fit.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- Otsuka Pharmaceutical - FDA Application Announcement
- Psychiatric Times - FDA Approval Coverage
- Centers for Disease Control and Prevention - Data and Statistics on Attention Differences
